Showing 4501-4510 of 20465 results for "".
- Recurrent Anaphylaxis Linked to Defensin Sensitizationhttps://reachmd.com/news/recurrent-anaphylaxis-linked-to-defensin-sensitization/2487774/Key Takeaways A case report about one 34-year-old man described 3 grade IV anaphylactic episodes after different meals in October 2022, one year later, and August 2025, with the diagnostic narrative ultimately converging on a defensin-related trigger hypothesis. Comp
- Single Early Pirarubicin After Nephroureterectomy Reduces Bladder Recurrencehttps://reachmd.com/news/single-early-pirarubicin-after-nephroureterectomy-reduces-bladder-recurrence/2487777/Key Takeaways Higher 3-year relapse-free survival was observed with pirarubicin than with observation. JCOG1403 was a randomized phase 3 study across 44 institutes that enrolled adults aged 20-80 years with previously untreated clinical stage 0a-III di
- PRP or Bmac Added To ACL Reconstruction Shows No 2-Year Benefithttps://reachmd.com/news/prp-or-bmac-added-to-acl-reconstruction-shows-no-2-year-benefit/2487786/Key Takeaways Platelet-rich plasma and bone marrow aspirate concentrate were not associated with better clinical outcomes at about 2 years after ACL reconstruction. MRI signal intensity of the intra-articular graft and the tunnel graft did not differ s
- Two-Year Outcomes in the PHARRLAP Rehabilitation Trialhttps://reachmd.com/news/two-year-outcomes-in-the-pharrlap-rehabilitation-trial/2487761/Key Takeaways Two-year recovery trajectories were broadly similar between groups after repair for acute avulsion involving at least 2 tendons. Accelerated rehabilitation was associated with a better 3-month SF-12 physical score and lower hamstring pain
- Prophylactic Dextrose Gel and School-Age Neurocognitive Outcomeshttps://reachmd.com/news/prophylactic-dextrose-gel-and-school-age-neurocognitive-outcomes/2487766/Key Takeaways School-age neurocognitive impairment was similar in children assigned to dextrose gel and placebo. Exploratory analyses found more emotional-behavioral difficulty and lower psychosocial function in the dextrose gel group. The inv
- Menopausal Hormone Therapy and Long-Term Mortality in a Danish Cohorthttps://reachmd.com/news/menopausal-hormone-therapy-and-long-term-mortality-in-a-danish-cohort/2487749/Key Takeaways Adjusted analyses did not indicate higher long-term all-cause mortality among women who used systemic menopausal hormone therapy. Overall cause-specific analyses did not show unequivocal differences in cardiovascular, cancer, or other-cau
- Primary Care CGM Linked to Better HbA1c and Fewer Acute Visitshttps://reachmd.com/news/primary-care-cgm-linked-to-better-hba1c-and-fewer-acute-visits/2487758/Key Takeaways Primary care CGM initiation was associated with larger 12-month HbA1c declines, with reductions of 0.66 percentage points among initiators and 0.17 percentage points among noninitiators. CGM initiation was also associated with lower risk
- Tamsulosin Deprescribing in Older Men With Lower Urinary Tract Symptomshttps://reachmd.com/news/tamsulosin-deprescribing-in-older-men-with-lower-urinary-tract-symptoms/2487765/Key Takeaways Investigators categorized 36.7% as having minimal or no effect, 36.7% as having a moderate effect, 13.3% as having a strong effect, and 13.3% as not tolerating the placebo run-in. Daily AUASI-based symptom tracking was used in a placebo-c
- Sirolimus-Eluting Balloon Strategy Versus Routine DES in De Novo Lesionshttps://reachmd.com/news/sirolimus-eluting-balloon-strategy-versus-routine-des-in-de-novo-lesions/2487757/Key Takeaways At 1 year, target vessel failure was reported in 5.3% of patients with the sirolimus-eluting balloon strategy and 4.4% with systematic DES implantation, and noninferiority was met in the intention-to-treat analysis. Bailout stenting was r
- Ensartinib After Resection in Alk-Positive NSCLChttps://reachmd.com/news/ensartinib-after-resection-in-alk-positive-nsclc/2487759/Key Takeaways In stage II to IIIB disease, ensartinib was associated with a hazard ratio of 0.20 for recurrence or death versus placebo. A similar disease-free survival advantage was reported in the overall randomized population at 24 months.